Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2022 2
2023 2
2024 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.
Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Ré R, de Portu S, Vorrink L, Shin J, Habteab A, Castañeda J, da Silva J, Cohen O; ADAPT study Group. Choudhary P, et al. Among authors: vorrink l. Lancet Diabetes Endocrinol. 2022 Oct;10(10):720-731. doi: 10.1016/S2213-8587(22)00212-1. Epub 2022 Sep 1. Lancet Diabetes Endocrinol. 2022. PMID: 36058207 Clinical Trial.
Efficacy and safety of automated insulin delivery in children aged 2-6 years (LENNY): an open-label, multicentre, randomised, crossover trial.
Battelino T, Kuusela S, Shetty A, Rabbone I, Cherubini V, Campbell F, Ahomäki R, Tuomaala AK, Peters C, Iafusco D, Sundaram P, Schiaffini R, Cellot J, Gulotta F, Di Piazza F, Cohen O; LENNY study group. Battelino T, et al. Lancet Diabetes Endocrinol. 2025 Aug;13(8):662-673. doi: 10.1016/S2213-8587(25)00091-9. Epub 2025 Jun 19. Lancet Diabetes Endocrinol. 2025. PMID: 40544853 Clinical Trial.
Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
Edd SN, Castañeda J, Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Ré R, Cellot J, de Portu S, Vorrink L, Shin J, van den Heuvel T, Cohen O; ADAPT study Group. Edd SN, et al. Among authors: vorrink l. Diabetes Obes Metab. 2023 Nov;25(11):3212-3222. doi: 10.1111/dom.15217. Epub 2023 Aug 8. Diabetes Obes Metab. 2023. PMID: 37551542 Clinical Trial.
Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes.
De Valk HW, Lablanche S, Bosi E, Choudhary P, Silva JD, Castaneda J, Vorrink L, De Portu S, Cohen O. De Valk HW, et al. Among authors: vorrink l. Diabetes Technol Ther. 2018 Nov;20(11):758-766. doi: 10.1089/dia.2018.0222. Epub 2018 Oct 16. Diabetes Technol Ther. 2018. PMID: 30325656
Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring.
van den Heuvel T, Kolassa R, Keuthage W, Kroeger J, Ré R, de Portu S, Vorrink L, Shin J, Castañeda J, Vigersky R, Cohen O. van den Heuvel T, et al. Among authors: vorrink l. J Diabetes Sci Technol. 2024 Sep;18(5):1132-1138. doi: 10.1177/19322968231161320. Epub 2023 Mar 22. J Diabetes Sci Technol. 2024. PMID: 36949671 Free PMC article. Clinical Trial.